A drug used to produce muscle relaxation (excepting neuromuscular blocking agents). Its primary clinical and therapeutic use is the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. Also used for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.
| Member | Definition | Class |
|---|
| 6-methoxybenzoxazolinone | A 2-benzoxazolinone that is substituted by a methoxy group at position 6. | 6-methoxy-2-benzoxazolinone; Coixol |
| 8-bromocyclic gmp | A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic GMP bearing an additional bromo substituent at position 8 on the guanine ring. A membrane permeable cGMP analogue that activates protein kinase G (PKG). It is 4.3-fold more potent than cGMP in activating PKG1alpha and promotes relaxation of tracheal and vascular smooth muscle tissue in vitro. | 8-bromo-3',5'-cyclic GMP |
| 8-bromocyclic gmp, sodium salt | An organic sodium salt having 8-bromoguanosine 3',5'-cyclic phosphate as the counterion. A membrane permeable cGMP analogue that activates protein kinase G (PKG). It is 4.3-fold more potent than cGMP in activating PKG1alpha and promotes relaxation of tracheal and vascular smooth muscle tissue in vitro. | sodium 8-bromo-3',5'-cyclic GMP |
| alprazolam | A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug. | alprazolam |
| atracurium | A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups. | atracurium |
| atracurium besylate | The bisbenzenesulfonate salt of atracurium. | atracurium besylate |
| baclofen | A monocarboxylic acid that is butanoic acid substituted by an amino group at position 4 and a 4-chlorophenyl group at position 3. It acts as a central nervous system depressant, GABA agonist and muscle relaxant. | baclofen zwitterion; baclofen |
| beta-erythroidine | An organic heterotetracyclic indole alkaloid isolated from the seeds and other parts of Erythrina species. It differs from the alpha isomer in having the double bond of the dihydropyranone ring located beta,gamma- to the lactone carbonyl group instead of alpha,beta-. | beta-erythroidine |
| carisoprodol | A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. | carisoprodol |
| chlormezanone | A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions. | chlormezanone |
| chlorphenesin | Glycerol in which the hydrogen of one of the primary hydroxy groups is substituted by a 4-chlorophenyl group. It has antifungal and antibacterial properties, and is used for treatment of cutaneous and vaginal infections. Its 1-carbamate is used as a skeletal muscle relaxant for the treatment of painful muscle spasm. | chlorphenesin |
| chlorphenesin carbamate | The carbamate ester of the primary hydroxy group of chlorphenesin. A centrally acting skeletal muscle relaxant, it is used in the symptomatic treatment of painful muscle spasm. | chlorphenesin carbamate |
| chlorzoxazone | A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm. | chlorzoxazone |
| cisatracurium | A diester that is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium, a quaternary ammonium ion consisting of pentane-1,5-diol with both hydroxy functions bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups. The active species in the skeletal muscle relaxant cisatracurium besylate. | cisatracurium |
| cyclobenzaprine | 5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm. | cyclobenzaprine |
| cyclobenzaprine hydrochloride | The hydrochloride salt of cyclobenzaprine. A centrally acting skeletal muscle relaxant, it is used in the symptomatic treatment of painful muscle spasm. | cyclobenzaprine hydrochloride |
| dantrolene | The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia. | dantrolene |
| decamethonium | A quaternary ammonium ion that is a depolarising muscle relaxant whose structure comprises a decane-1,10-diamine core in which each amino group carries three methyl substituents. | decamethonium |
| dyphylline | An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs. | dyphylline |
| glaucine | An aporphine alkaloid that is (S)-1,2,9,10-tetrahydroxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline in which the four phenolic hydrogens have been replaced by methyl groups. | (S)-glaucine |
| lanperisone | A 2-methyl-3-(pyrrolidin-1-yl)-1-[4-(trifluoromethyl)phenyl]propan-1-one in which the methyl group at position 2 adopts R-configuration. It is a muscle relaxant and induces ferroptosis in cancer cells. | lanperisone |
| midazolam | An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively. | midazolam |
| midazolam hydrochloride | The hydrochloride salt of midazolam. | midazolam hydrochloride |
| nitroglycerin | A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain. | nitroglycerin |
| orphenadrine | A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol. | orphenadrine |
| orphenadrine citrate | A citrate salt which comprises equimolar amounts of orphenadrine and citric acid. | orphenadrine citrate |
| orphenadrine hydrochloride | A hydrochloride comprising equimolar amounts of ophenadrine and hydrogen chloride. | orphenadrine hydrochloride |
| oxybutynin | A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder. | 4-(diethylamino)but-2-yn-1-ol; oxybutynin |
| pancuronium | A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant. | pancuronium |
| pancuronium bromide | A bromide salt consisting of two bromide ions and one pancuronium dication. | pancuronium bromide |
| pridinol | A piperidine substituted at position 1 by a 3-hydroxy-3,3-diphenylpropyl group. | pridinol |
| quinine | A cinchona alkaloid that is cinchonidine in which the hydrogen at the 6-position of the quinoline ring is substituted by methoxy. | quinine |
| rocuronium | A 5alpha-androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents. | rocuronium |
| rocuronium bromide | The organic bromide salt of a 5alpha androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents. | rocuronium bromide |
| succinylcholine | A quaternary ammonium ion that is the bis-choline ester of succinic acid. | succinylcholine |
| suxamethonium chloride | A chloride salt in which the negative charge of the chloride ions is balanced by succinylcholine dications. | succinylcholine chloride (anhydrous) |
| theophylline | A dimethylxanthine having the two methyl groups located at positions 1 and 3. It is structurally similar to caffeine and is found in green and black tea. | theophylline |
| tizanidine | 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites. | tizanidine |
| tolterodine | | tolterodine |
| tubocurarine | A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare. | tubocurarine |
| vecuronium | A 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidino- and 16beta-N-methylpiperidinium substituents. | vecuronium |
| vecuronium bromide | The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents. | vecuronium bromide |
| xylazine | A methyl benzene that is 1,3-dimethylbenzene which is substituted by a 5,6-dihydro-4H-1,3-thiazin-2-ylnitrilo group at position 2. It is an alpha2 adrenergic receptor agonist and frequently used in veterinary medicine as an emetic and sedative with analgesic and muscle relaxant properties. | xylazine |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 1 | 1 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| 67.9K protein | Vaccinia virus | Potency | 3.1623 | 1 | 1 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 24.9948 | 3 | 8 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 4.5111 | 1 | 3 |
| AR protein | Homo sapiens (human) | Potency | 14.3286 | 9 | 24 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 19.2492 | 2 | 6 |
| arylsulfatase A | Homo sapiens (human) | Potency | 16.5631 | 1 | 8 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 12.5741 | 4 | 8 |
| Ataxin-2 | Homo sapiens (human) | Potency | 18.0206 | 2 | 3 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 5.3567 | 1 | 5 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 21.7189 | 2 | 4 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 37.9330 | 1 | 2 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 16.4816 | 1 | 1 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 71.1491 | 2 | 8 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 34.3810 | 1 | 3 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 17.1965 | 1 | 8 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 50.3155 | 1 | 2 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 100.0000 | 1 | 1 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 39.1512 | 1 | 2 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 27.5130 | 2 | 9 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 0.7943 | 1 | 1 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 35.1465 | 2 | 5 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 13.2922 | 1 | 3 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 11.8621 | 1 | 14 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 15.4972 | 1 | 6 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 4.2103 | 2 | 6 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 14.3587 | 2 | 12 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 5.0511 | 1 | 4 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 1.0611 | 2 | 5 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 26.1216 | 1 | 1 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 100.0000 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 63.1356 | 1 | 3 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| endonuclease IV | Escherichia coli | Potency | 25.1189 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 13.0995 | 9 | 36 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 33.4915 | 1 | 1 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 23.5902 | 4 | 5 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 23.3167 | 1 | 18 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 15.5778 | 4 | 13 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 11.9080 | 1 | 3 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 8.4368 | 1 | 3 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 33.1734 | 1 | 2 |
| G | Vesicular stomatitis virus | Potency | 13.2922 | 1 | 3 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 4.2103 | 1 | 3 |
| geminin | Homo sapiens (human) | Potency | 9.6795 | 2 | 13 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 12.1700 | 2 | 17 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| GLS protein | Homo sapiens (human) | Potency | 18.3530 | 2 | 6 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 15.1794 | 3 | 13 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 15.8613 | 1 | 2 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 11.2202 | 1 | 1 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 19.2203 | 1 | 6 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 18.6278 | 1 | 3 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 13.2922 | 1 | 3 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 3.1623 | 2 | 2 |
| IDH1 | Homo sapiens (human) | Potency | 16.1795 | 1 | 3 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 13.2922 | 1 | 6 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 5.5461 | 1 | 6 |
| Interferon beta | Homo sapiens (human) | Potency | 12.5004 | 2 | 6 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 13.3863 | 1 | 15 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 0.7943 | 1 | 1 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 15.4674 | 1 | 2 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 20.2466 | 1 | 2 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 7.3858 | 2 | 7 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 0.7943 | 1 | 1 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 12.5694 | 1 | 2 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 6.7933 | 2 | 6 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 33.6486 | 2 | 10 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 13.1950 | 1 | 2 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 23.9145 | 1 | 1 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 42.1632 | 1 | 1 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 11.1224 | 2 | 5 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 18.4746 | 2 | 7 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 112.9460 | 1 | 2 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 7.9470 | 2 | 6 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 72.9082 | 1 | 3 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 15.5568 | 1 | 4 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 50.0249 | 1 | 3 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 66.9675 | 1 | 3 |
| polyprotein | Zika virus | Potency | 33.1734 | 1 | 2 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 19.2203 | 1 | 3 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 10.8637 | 1 | 6 |
| PPM1D protein | Homo sapiens (human) | Potency | 11.7086 | 1 | 2 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 24.6540 | 3 | 12 |
| progesterone receptor | Homo sapiens (human) | Potency | 14.9250 | 2 | 2 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 5.6234 | 1 | 1 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 17.5558 | 2 | 12 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 4.9288 | 1 | 2 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 33.9351 | 1 | 5 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 34.2108 | 3 | 15 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 21.0815 | 2 | 11 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 14.2702 | 3 | 3 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 26.6795 | 1 | 1 |
| shiga toxin 1 B subunit | Escherichia coli O157:H7 | Potency | 0.3177 | 1 | 1 |
| shiga toxin 1 variant A subunit | Escherichia coli O157:H7 | Potency | 0.3177 | 1 | 1 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 10.6822 | 1 | 1 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 10.6822 | 1 | 1 |
| Smad3 | Homo sapiens (human) | Potency | 0.1061 | 1 | 2 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 13.4684 | 1 | 6 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 1.1220 | 1 | 1 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 11.2202 | 1 | 1 |
| TDP1 protein | Homo sapiens (human) | Potency | 24.1161 | 2 | 27 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 25.1189 | 1 | 1 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 7.5005 | 1 | 9 |
| Thrombopoietin | Homo sapiens (human) | Potency | 7.9874 | 2 | 4 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 27.2711 | 3 | 25 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 54.6352 | 3 | 3 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 20.2751 | 6 | 14 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 14.0884 | 2 | 2 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 7.0795 | 1 | 1 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 22.3872 | 1 | 1 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 0.4521 | 2 | 3 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 17.9044 | 2 | 10 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 15.6964 | 1 | 2 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 100.0000 | 1 | 1 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 15.8613 | 1 | 2 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 43.0855 | 2 | 2 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 | 0.4360 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.6857 | 3 | 3 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 | 2.0915 | 1 | 2 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.9270 | 2 | 3 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 | 0.5340 | 1 | 1 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.3040 | 2 | 2 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | IC50 | 0.5340 | 1 | 1 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 0.2800 | 1 | 1 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 | 1.1210 | 1 | 1 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 0.5210 | 1 | 1 |
| 5-hydroxytryptamine receptor 7 | Cavia porcellus (domestic guinea pig) | IC50 | 32.1000 | 1 | 4 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Ki | 0.0430 | 1 | 1 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 | 5.9000 | 1 | 1 |
| Acetylcholinesterase | Torpedo marmorata (marbled electric ray) | IC50 | 1.0630 | 1 | 1 |
| Acetylcholinesterase | Homo sapiens (human) | Ki | 3,000.2300 | 2 | 2 |
| Acetylcholinesterase | Mus musculus (house mouse) | Ki | 8.3200 | 2 | 3 |
| Adenosine receptor A1 | Bos taurus (cattle) | IC50 | 1,006,650,005.0433 | 3 | 3 |
| Adenosine receptor A1 | Homo sapiens (human) | IC50 | 17.1040 | 1 | 1 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | IC50 | 19.0000 | 2 | 2 |
| Adenosine receptor A1 | Bos taurus (cattle) | Ki | 4.1143 | 7 | 7 |
| Adenosine receptor A1 | Cavia porcellus (domestic guinea pig) | Ki | 21.3333 | 6 | 6 |
| Adenosine receptor A1 | Gallus gallus (chicken) | Ki | 6.0000 | 1 | 1 |
| Adenosine receptor A1 | Homo sapiens (human) | Ki | 6.6399 | 18 | 18 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | Ki | 9.2781 | 31 | 37 |
| Adenosine receptor A2a | Homo sapiens (human) | IC50 | 12.0070 | 1 | 1 |
| Adenosine receptor A2a | Cavia porcellus (domestic guinea pig) | Ki | 14.0000 | 2 | 2 |
| Adenosine receptor A2a | Homo sapiens (human) | Ki | 8.5486 | 27 | 27 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | Ki | 15.9652 | 24 | 31 |
| Adenosine receptor A2b | Homo sapiens (human) | Ki | 10.1426 | 19 | 19 |
| Adenosine receptor A2b | Rattus norvegicus (Norway rat) | Ki | 15.3896 | 18 | 24 |
| Adenosine receptor A3 | Homo sapiens (human) | Ki | 54.8657 | 20 | 20 |
| Adenosine receptor A3 | Rattus norvegicus (Norway rat) | Ki | 45.4056 | 8 | 9 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 2.6306 | 1 | 2 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | Ki | 2.6083 | 1 | 2 |
| Alkaline phosphatase, tissue-nonspecific isozyme | Homo sapiens (human) | IC50 | 52.5000 | 2 | 2 |
| Alkaline phosphatase, tissue-nonspecific isozyme | Homo sapiens (human) | Ki | 82.0000 | 1 | 1 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 2.1560 | 1 | 1 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.8090 | 1 | 1 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 1.8950 | 1 | 1 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.8650 | 1 | 1 |
| Amyloid-beta precursor protein | Homo sapiens (human) | Ki | 0.0059 | 1 | 1 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 11 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 | 115.8917 | 12 | 12 |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | IC50 | 41.5000 | 4 | 4 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | Ki | 12.0000 | 1 | 1 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 211.3428 | 4 | 25 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Homo sapiens (human) | IC50 | 320.0000 | 1 | 1 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Bos taurus (cattle) | IC50 | 340.4000 | 5 | 5 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Bos taurus (cattle) | IC50 | 300.5000 | 4 | 4 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Homo sapiens (human) | IC50 | 320.0000 | 1 | 1 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Homo sapiens (human) | IC50 | 320.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | IC50 | 574.2500 | 4 | 4 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | Ki | 530.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Rattus norvegicus (Norway rat) | Ki | 530.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | IC50 | 527.7500 | 4 | 4 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | Ki | 530.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Rattus norvegicus (Norway rat) | Ki | 530.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | IC50 | 637.0000 | 3 | 3 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | Ki | 530.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Rattus norvegicus (Norway rat) | Ki | 530.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | IC50 | 637.0000 | 3 | 3 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | Ki | 530.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Rattus norvegicus (Norway rat) | Ki | 530.0000 | 1 | 1 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 11 |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 | 210.0000 | 1 | 1 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | IC50 | 300.0000 | 2 | 2 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | IC50 | 300.0000 | 2 | 2 |
| Chain A, Pyridoxal kinase | Homo sapiens (human) | Ki | 50.0000 | 1 | 2 |
| Chitotriosidase-1 | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 2 |
| Cholecystokinin receptor type A | Cavia porcellus (domestic guinea pig) | IC50 | 64.0000 | 1 | 1 |
| Cholecystokinin receptor type A | Rattus norvegicus (Norway rat) | IC50 | 64.0000 | 1 | 1 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 | 0.6000 | 1 | 1 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Cytochrome P450 2D1 | Rattus norvegicus (Norway rat) | IC50 | 46.5000 | 1 | 1 |
| Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | IC50 | 0.0940 | 1 | 1 |
| Cytochrome P450 2D3 | Rattus norvegicus (Norway rat) | IC50 | 12.0000 | 1 | 1 |
| Cytochrome P450 2D4 | Rattus norvegicus (Norway rat) | IC50 | 1.7000 | 1 | 1 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 0.5828 | 5 | 5 |
| Cytochrome P450 2D6 | Homo sapiens (human) | Ki | 15.0000 | 1 | 1 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 2.7427 | 3 | 3 |
| D | Rattus norvegicus (Norway rat) | Ki | 2.9000 | 1 | 1 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 2.8000 | 1 | 1 |
| D(3) dopamine receptor | Homo sapiens (human) | IC50 | 0.4288 | 1 | 1 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 0.1456 | 1 | 1 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.0006 | 1 | 1 |
| Endochitinase B1 | Aspergillus fumigatus | IC50 | 1,000.0000 | 1 | 2 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Homo sapiens (human) | Ki | 0.0008 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Homo sapiens (human) | Ki | 0.0006 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Homo sapiens (human) | Ki | 0.0014 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Homo sapiens (human) | Ki | 0.0015 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Homo sapiens (human) | Ki | 0.0011 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Homo sapiens (human) | Ki | 0.0011 | 4 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Ki | 0.0026 | 2 | 2 |
| Gamma-aminobutyric acid type B receptor subunit 1 | Homo sapiens (human) | IC50 | 0.0500 | 1 | 1 |
| Gamma-aminobutyric acid type B receptor subunit 1 | Rattus norvegicus (Norway rat) | IC50 | 0.2762 | 4 | 6 |
| Gamma-aminobutyric acid type B receptor subunit 1 | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Gamma-aminobutyric acid type B receptor subunit 2 | Homo sapiens (human) | IC50 | 0.0500 | 1 | 1 |
| Gamma-aminobutyric acid type B receptor subunit 2 | Rattus norvegicus (Norway rat) | IC50 | 0.2762 | 4 | 6 |
| Gamma-aminobutyric acid type B receptor subunit 2 | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Gamma-aminobutyric acid type B receptor subunit 2 | Rattus norvegicus (Norway rat) | Ki | 0.2200 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2C | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2D | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3A | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3B | Homo sapiens (human) | Ki | 6.0000 | 1 | 1 |
| High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| Histamine H1 receptor | Homo sapiens (human) | IC50 | 49.4823 | 2 | 2 |
| Histamine H1 receptor | Homo sapiens (human) | Ki | 0.1440 | 1 | 1 |
| Histamine H2 receptor | Homo sapiens (human) | IC50 | 6.9610 | 1 | 1 |
| Histamine H2 receptor | Homo sapiens (human) | Ki | 6.8450 | 1 | 1 |
| Histamine H3 receptor | Homo sapiens (human) | IC50 | 0.8200 | 1 | 1 |
| Histidine-rich protein PFHRP-II | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 7,400,000.0000 | 1 | 1 |
| Intestinal-type alkaline phosphatase | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| Lethal(3)malignant brain tumor-like protein 1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Lethal(3)malignant brain tumor-like protein 3 | Homo sapiens (human) | IC50 | 54.0000 | 1 | 1 |
| Lethal(3)malignant brain tumor-like protein 4 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| MBT domain-containing protein 1 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | Ki | 0.0008 | 1 | 1 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 25.4333 | 2 | 3 |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | IC50 | 60.2333 | 2 | 3 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 121.7818 | 1 | 11 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | IC50 | 0.0758 | 1 | 2 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 0.0083 | 4 | 5 |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Ki | 0.0059 | 1 | 1 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | IC50 | 0.2015 | 1 | 2 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 0.0266 | 5 | 7 |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | Ki | 0.0093 | 2 | 3 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | IC50 | 0.0889 | 1 | 2 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Ki | 0.0061 | 7 | 9 |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | Ki | 0.0044 | 2 | 3 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | IC50 | 0.0635 | 1 | 2 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 0.0060 | 3 | 4 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | IC50 | 0.0156 | 1 | 2 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 0.0097 | 3 | 4 |
| Neuronal acetylcholine receptor subunit alpha-3 | Homo sapiens (human) | IC50 | 1.7000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Ki | 1.1000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Ki | 1.1000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-4 | Homo sapiens (human) | IC50 | 1.7000 | 1 | 1 |
| Nischarin | Homo sapiens (human) | Ki | 0.0283 | 1 | 2 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | IC50 | 2,904.0000 | 1 | 1 |
| Phosphodiesterase | Bos taurus (cattle) | IC50 | 250.3333 | 6 | 6 |
| Phosphodiesterase | Bos taurus (cattle) | Ki | 77.0000 | 1 | 1 |
| Phospholipase A-2-activating protein | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| Potassium channel subfamily K member 2 | Homo sapiens (human) | IC50 | 3.8500 | 1 | 1 |
| Potassium voltage-gated channel subfamily D member 3 | Homo sapiens (human) | IC50 | 12.5892 | 1 | 1 |
| Potassium voltage-gated channel subfamily E member 1 | Homo sapiens (human) | IC50 | 79.4328 | 1 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 0.2330 | 5 | 5 |
| Potassium voltage-gated channel subfamily KQT member 1 | Homo sapiens (human) | IC50 | 79.4328 | 1 | 1 |
| Renin | Homo sapiens (human) | Ki | 2.3250 | 1 | 2 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 | 100.0000 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | IC50 | 100.0000 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | IC50 | 0.0242 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | Ki | 7.9000 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 0.0102 | 1 | 1 |
| Small conductance calcium-activated potassium channel protein 1 | Rattus norvegicus (Norway rat) | IC50 | 6.8000 | 1 | 1 |
| Small conductance calcium-activated potassium channel protein 2 | Rattus norvegicus (Norway rat) | IC50 | 6.8000 | 1 | 1 |
| Small conductance calcium-activated potassium channel protein 3 | Rattus norvegicus (Norway rat) | IC50 | 6.8000 | 1 | 1 |
| Small conductance calcium-activated potassium channel protein 3 | Rattus norvegicus (Norway rat) | Ki | 5.9000 | 1 | 1 |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | IC50 | 18.9662 | 2 | 2 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | IC50 | 0.0855 | 1 | 1 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 0.0679 | 1 | 1 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 2.6306 | 1 | 2 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 2.6083 | 1 | 2 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 0.4580 | 1 | 1 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 0.2430 | 1 | 1 |
| Solute carrier family 22 member 1 | Mus musculus (house mouse) | IC50 | 0.2800 | 1 | 1 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | IC50 | 2.0333 | 3 | 3 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | Ki | 2.6150 | 2 | 2 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 | 54.7333 | 2 | 3 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | Ki | 94.6500 | 2 | 4 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 | 28.2667 | 2 | 3 |
| Solute carrier family 22 member 2 | Mus musculus (house mouse) | IC50 | 2.8000 | 1 | 1 |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | IC50 | 25.5000 | 2 | 2 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | Ki | 3.4000 | 1 | 1 |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | Ki | 55.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1A1 | Rattus norvegicus (Norway rat) | Ki | 76.7000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1A4 | Rattus norvegicus (Norway rat) | Ki | 3.8100 | 1 | 1 |
| Thyroid hormone receptor beta | Rattus norvegicus (Norway rat) | Ki | 14.0000 | 1 | 1 |
| Translocator protein | Rattus norvegicus (Norway rat) | Ki | 0.0020 | 1 | 1 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | IC50 | 200.2222 | 1 | 9 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | IC50 | 200.2222 | 1 | 9 |
| UDP-glucuronosyltransferase 1A4 | Homo sapiens (human) | IC50 | 200.2222 | 1 | 9 |
| UDP-glucuronosyltransferase 2B10 | Homo sapiens (human) | IC50 | 200.2222 | 1 | 9 |
| UDP-glucuronosyltransferase 2B7 | Homo sapiens (human) | IC50 | 200.2222 | 1 | 9 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 | 25.1189 | 1 | 1 |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |